Clinical isolates of ST131 bla OXA-244-positive Escherichia coli, Italy, December 2022 to July 2023

Euro Surveill. 2024 Feb;29(8):2400073. doi: 10.2807/1560-7917.ES.2024.29.8.2400073.

Abstract

The dissemination of carbapenemase-producing Escherichia coli, although still at low level, should be continuously monitored. OXA-244 is emerging in Europe, mainly in E. coli. In Italy, this carbapenemase was reported from an environmental river sample in 2019. We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.

Keywords: Escherichia coli; OXA-244; ST131; WGS; high-risk clone; surveillance.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenem-Resistant Enterobacteriaceae*
  • Escherichia coli / genetics
  • Escherichia coli Infections* / diagnosis
  • Europe
  • Humans
  • Italy / epidemiology
  • beta-Lactamases / genetics

Substances

  • beta-Lactamases
  • Anti-Bacterial Agents